Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) EBITDA (2016 - 2025)

Historic EBITDA for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to $4.9 million.

  • Sanara MedTech's EBITDA rose 9146.54% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 4879.1%. This contributed to the annual value of $2.7 million for FY2024, which is 201502.59% up from last year.
  • As of Q3 2025, Sanara MedTech's EBITDA stood at $4.9 million, which was up 9146.54% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Sanara MedTech's EBITDA ranged from a high of $4.9 million in Q3 2025 and a low of -$3.3 million during Q4 2021
  • Over the past 5 years, Sanara MedTech's median EBITDA value was -$1.0 million (recorded in 2021), while the average stood at -$561039.1.
  • The largest annual percentage gain for Sanara MedTech's EBITDA in the last 5 years was 86086.88% (2024), contrasted with its biggest fall of 63560.14% (2024).
  • Sanara MedTech's EBITDA (Quarter) stood at -$3.3 million in 2021, then increased by 9.14% to -$3.0 million in 2022, then skyrocketed by 114.88% to $448909.0 in 2023, then crashed by 635.6% to -$2.4 million in 2024, then soared by 304.14% to $4.9 million in 2025.
  • Its last three reported values are $4.9 million in Q3 2025, $2.7 million for Q2 2025, and $657969.0 during Q1 2025.